Chemotherapy options for the elderly patient with advanced non-small cell lung cancer.

Hdl Handle:
http://hdl.handle.net/10147/208997
Title:
Chemotherapy options for the elderly patient with advanced non-small cell lung cancer.
Authors:
Hennessy, B T; Hanrahan, E O; Breathnach, O S
Affiliation:
Department of Medical Oncology, Cork University Hospital, Cork, Ireland., bryanhen@gofree.indigo.ie
Citation:
Oncologist. 2003;8(3):270-7.
Journal:
The oncologist
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/208997
PubMed ID:
12773749
Abstract:
Combination chemotherapy has been shown to improve overall survival compared with best supportive care in patients with advanced non-small cell lung cancer (NSCLC). The survival advantage is modest and was initially demonstrated with cisplatin-containing regimens in a large meta-analysis of randomized trials reported in 1995. Newer chemotherapy combinations have been shown to be better tolerated than older cisplatin-based combinations, and some trials have also shown greater efficacy and survival benefits with these newer combinations. Combination chemotherapy is, therefore, the currently accepted standard of care for patients with good performance statuses aged less than 70 years with advanced NSCLC. However, there are limited data from clinical trials to support the use of combination chemotherapy in elderly patients over 70 years of age with advanced NSCLC. Subgroup analyses of large randomized phase III trials suggest that elderly patients with good performance statuses do as well as younger patients treated with combination chemotherapy. There are few randomized trials reported that evaluate chemotherapy in patients aged greater than 70 years only. Based on data from trials performed by an Italian group, single-agent vinorelbine has been shown to have significant activity in elderly patients with advanced NSCLC and to be well tolerated by those patients with Eastern Cooperative Oncology Group performance statuses of two or less, with associated improvements in measures of global health.
Language:
eng
MeSH:
Aged; Antineoplastic Agents/*therapeutic use; Carcinoma, Non-Small-Cell Lung/*drug therapy; Clinical Trials as Topic; Humans; Lung Neoplasms/*drug therapy; Palliative Care; United States
ISSN:
1083-7159 (Print); 1083-7159 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorHennessy, B Ten_GB
dc.contributor.authorHanrahan, E Oen_GB
dc.contributor.authorBreathnach, O Sen_GB
dc.date.accessioned2012-02-03T15:09:31Z-
dc.date.available2012-02-03T15:09:31Z-
dc.date.issued2012-02-03T15:09:31Z-
dc.identifier.citationOncologist. 2003;8(3):270-7.en_GB
dc.identifier.issn1083-7159 (Print)en_GB
dc.identifier.issn1083-7159 (Linking)en_GB
dc.identifier.pmid12773749en_GB
dc.identifier.urihttp://hdl.handle.net/10147/208997-
dc.description.abstractCombination chemotherapy has been shown to improve overall survival compared with best supportive care in patients with advanced non-small cell lung cancer (NSCLC). The survival advantage is modest and was initially demonstrated with cisplatin-containing regimens in a large meta-analysis of randomized trials reported in 1995. Newer chemotherapy combinations have been shown to be better tolerated than older cisplatin-based combinations, and some trials have also shown greater efficacy and survival benefits with these newer combinations. Combination chemotherapy is, therefore, the currently accepted standard of care for patients with good performance statuses aged less than 70 years with advanced NSCLC. However, there are limited data from clinical trials to support the use of combination chemotherapy in elderly patients over 70 years of age with advanced NSCLC. Subgroup analyses of large randomized phase III trials suggest that elderly patients with good performance statuses do as well as younger patients treated with combination chemotherapy. There are few randomized trials reported that evaluate chemotherapy in patients aged greater than 70 years only. Based on data from trials performed by an Italian group, single-agent vinorelbine has been shown to have significant activity in elderly patients with advanced NSCLC and to be well tolerated by those patients with Eastern Cooperative Oncology Group performance statuses of two or less, with associated improvements in measures of global health.en_GB
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshAntineoplastic Agents/*therapeutic useen_GB
dc.subject.meshCarcinoma, Non-Small-Cell Lung/*drug therapyen_GB
dc.subject.meshClinical Trials as Topicen_GB
dc.subject.meshHumansen_GB
dc.subject.meshLung Neoplasms/*drug therapyen_GB
dc.subject.meshPalliative Careen_GB
dc.subject.meshUnited Statesen_GB
dc.titleChemotherapy options for the elderly patient with advanced non-small cell lung cancer.en_GB
dc.contributor.departmentDepartment of Medical Oncology, Cork University Hospital, Cork, Ireland., bryanhen@gofree.indigo.ieen_GB
dc.identifier.journalThe oncologisten_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.